{"id":76808,"date":"2026-08-27T14:54:14","date_gmt":"2026-08-27T06:54:14","guid":{"rendered":"https:\/\/flcube.com\/?p=76808"},"modified":"2026-08-27T14:54:15","modified_gmt":"2026-08-27T06:54:15","slug":"hansoh-pharmaceutical-posts-35-8-profit-growth-in-1h-2026-as-innovative-drugs-reach-85-of-revenue-first-newco-out-licensing-deal-marked","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76808","title":{"rendered":"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hansoh Pharmaceutical Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/3692:HKG\">HKG: 3692<\/a>) released its interim results for the first half of 2026, reporting revenue of approximately <strong>RMB 8.30 billion<\/strong>, up <strong>11.7%<\/strong> year on year, and profit of approximately <strong>RMB 4.26 billion<\/strong>, a <strong>35.8%<\/strong> year\u2011on\u2011year increase. Innovative drug revenue reached approximately <strong>RMB 7.09 billion<\/strong>, representing <strong>85.4%<\/strong> of total revenue, while the company executed its first <strong>Newco\u2011model out\u2011licensing<\/strong> transaction \u2014 a landmark in its internationalization strategy \u2014 and continued to expand its flagship EGFR\u2011TKI <strong>Ameile (almonertinib)<\/strong> globally.<\/p>\n\n\n\n<h2 id=\"h-financial-highlights-1h-2026\" class=\"wp-block-heading\">Financial Highlights \u2013 1H 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>1H 2026<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td>Total Revenue<\/td><td>~RMB 8.30 billion<\/td><td>+11.7%<\/td><\/tr><tr><td>Profit<\/td><td>~RMB 4.26 billion<\/td><td>+35.8%<\/td><\/tr><tr><td>Innovative Drug Revenue<\/td><td>~RMB 7.09 billion<\/td><td>85.4% of total<\/td><\/tr><tr><td>Innovative Drug Product Sales Growth<\/td><td>\u2014<\/td><td>+21.6%<\/td><\/tr><tr><td>Oncology Product Revenue<\/td><td>~RMB 5.47 billion<\/td><td>65.9% of total<\/td><\/tr><tr><td>R&amp;D Expenditure<\/td><td>~RMB 1.74 billion<\/td><td>+20.7% (~20.9% of revenue)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-commercial-performance-innovative-drugs-amp-ameile-franchise\" class=\"wp-block-heading\">Commercial Performance \u2013 Innovative Drugs &amp; Ameile Franchise<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation\u2011Driven Mix:<\/strong> Innovative drug revenue of approximately RMB 7.09 billion now accounts for 85.4% of total revenue, with innovative drug product sales growing approximately <strong>21.6%<\/strong> year on year<\/li>\n\n\n\n<li><strong>Oncology Anchor:<\/strong> Oncology products generated approximately <strong>RMB 5.47 billion<\/strong>, representing 65.9% of total revenue<\/li>\n\n\n\n<li><strong>Ameile (almonertinib) Milestones:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Now approved for <strong>five indications<\/strong> in lung cancer, continuing to achieve breakthroughs<\/li>\n\n\n\n<li>In 2026, successively approved for marketing in the <strong>European Union<\/strong> and the <strong>Macau Special Administrative Region of China<\/strong>, under the overseas brand name <strong>Aumseqa<\/strong> \u2014 extending the franchise beyond China<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pipeline-progress-1h-2026-execution\" class=\"wp-block-heading\">Pipeline Progress \u2013 1H 2026 Execution<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Count (Reporting Period)<\/th><\/tr><\/thead><tbody><tr><td>Innovative drug clinical trials being advanced<\/td><td>70+ (covering 40+ candidate innovative drugs)<\/td><\/tr><tr><td>New drug applications accepted for review<\/td><td>3<\/td><\/tr><tr><td>New Phase 3 pivotal registration trials initiated<\/td><td>3<\/td><\/tr><tr><td>New candidate innovative drugs receiving first\u2011time clinical trial approval<\/td><td>4<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-collaboration-hs-20118-newco-out-licensing\" class=\"wp-block-heading\">Strategic Collaboration \u2013 HS\u201120118 Newco Out\u2011Licensing<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Asset<\/td><td><strong>HS\u201120118<\/strong>, IL\u201123 receptor antagonist<\/td><\/tr><tr><td>Partner<\/td><td><strong>Avere Therapeutics<\/strong> (overseas rights)<\/td><\/tr><tr><td>Transaction Value<\/td><td>Exceeding <strong>USD 2.3 billion<\/strong> total<\/td><\/tr><tr><td>Deal Date<\/td><td>June 2026<\/td><\/tr><tr><td>Follow\u2011On Event<\/td><td>Avere merged with <strong>NextCure, Inc.<\/strong> (Nasdaq: NXTC) in July 2026<\/td><\/tr><tr><td>Strategic Significance<\/td><td>Hansoh&#8217;s <strong>first Newco model<\/strong> out\u2011licensing transaction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The HS\u201120118 transaction marks <strong>Hansoh Pharma&#8217;s first adoption of the Newco model<\/strong> for out\u2011licensing, demonstrating a more diversified and mature internationalization path that balances upfront economics with retained upside through the Nasdaq\u2011listed successor entity.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Profit Quality Inflection:<\/strong> Profit growth of 35.8% outpacing 11.7% revenue growth reflects operating leverage from the 85.4% innovative\u2011drug mix, validating Hansoh&#8217;s transformation from generic\u2011heavy to innovation\u2011driven.<\/li>\n\n\n\n<li><strong>Ameile Globalization:<\/strong> EU and Macau approvals under the Aumseqa brand establish almonertinib as a genuinely international third\u2011generation EGFR\u2011TKI, with further geographic expansion as the key commercial catalyst.<\/li>\n\n\n\n<li><strong>Newco Model Precedent:<\/strong> The USD 2.3 billion HS\u201120118 deal and subsequent Avere\u2013NextCure merger create a replicable template for Hansoh to monetize overseas rights across its 40+ candidate innovative drugs.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Three NDAs under review, three new Phase 3 readouts as they mature, HS\u201120118 clinical progression under the merged NextCure entity, and further out\u2011licensing transactions building on the Newco precedent.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief is for informational purposes only and does not constitute investment advice. Interim results are as reported by the Company; statements regarding pipeline development, approvals, and future financial performance are forward\u2011looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements and filings from Hansoh Pharmaceutical Group for authoritative details.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082600590.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082600590.\"><\/object><a id=\"wp-block-file--media-1a1282d4-fee0-4d58-b52d-047b74a73052\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082600590.pdf\">2026082600590<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082600590.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1a1282d4-fee0-4d58-b52d-047b74a73052\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76811,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,4908],"tags":[27,363,1182],"class_list":["post-76808","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-pic","tag-finanical-reports","tag-hansoh-pharmaceutical","tag-hkg-3692"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026, reporting revenue of approximately RMB 8.30 billion, up 11.7% year on year, and profit of approximately RMB 4.26 billion, a 35.8% year\u2011on\u2011year increase. Innovative drug revenue reached approximately RMB 7.09 billion, representing 85.4% of total revenue, while the company executed its first Newco\u2011model out\u2011licensing transaction \u2014 a landmark in its internationalization strategy \u2014 and continued to expand its flagship EGFR\u2011TKI Ameile (almonertinib) globally.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76808\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026, reporting revenue of approximately RMB 8.30 billion, up 11.7% year on year, and profit of approximately RMB 4.26 billion, a 35.8% year\u2011on\u2011year increase. Innovative drug revenue reached approximately RMB 7.09 billion, representing 85.4% of total revenue, while the company executed its first Newco\u2011model out\u2011licensing transaction \u2014 a landmark in its internationalization strategy \u2014 and continued to expand its flagship EGFR\u2011TKI Ameile (almonertinib) globally.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76808\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T06:54:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-27T06:54:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2705.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked\",\"datePublished\":\"2026-08-27T06:54:14+00:00\",\"dateModified\":\"2026-08-27T06:54:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808\"},\"wordCount\":531,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2705.webp\",\"keywords\":[\"Finanical Reports\",\"Hansoh Pharmaceutical\",\"HKG: 3692\"],\"articleSection\":[\"Company\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76808#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76808\",\"name\":\"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2705.webp\",\"datePublished\":\"2026-08-27T06:54:14+00:00\",\"dateModified\":\"2026-08-27T06:54:15+00:00\",\"description\":\"Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026, reporting revenue of approximately RMB 8.30 billion, up 11.7% year on year, and profit of approximately RMB 4.26 billion, a 35.8% year\u2011on\u2011year increase. Innovative drug revenue reached approximately RMB 7.09 billion, representing 85.4% of total revenue, while the company executed its first Newco\u2011model out\u2011licensing transaction \u2014 a landmark in its internationalization strategy \u2014 and continued to expand its flagship EGFR\u2011TKI Ameile (almonertinib) globally.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76808\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2705.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2705.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76808#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026, reporting revenue of approximately RMB 8.30 billion, up 11.7% year on year, and profit of approximately RMB 4.26 billion, a 35.8% year\u2011on\u2011year increase. Innovative drug revenue reached approximately RMB 7.09 billion, representing 85.4% of total revenue, while the company executed its first Newco\u2011model out\u2011licensing transaction \u2014 a landmark in its internationalization strategy \u2014 and continued to expand its flagship EGFR\u2011TKI Ameile (almonertinib) globally.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76808","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked","og_description":"Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026, reporting revenue of approximately RMB 8.30 billion, up 11.7% year on year, and profit of approximately RMB 4.26 billion, a 35.8% year\u2011on\u2011year increase. Innovative drug revenue reached approximately RMB 7.09 billion, representing 85.4% of total revenue, while the company executed its first Newco\u2011model out\u2011licensing transaction \u2014 a landmark in its internationalization strategy \u2014 and continued to expand its flagship EGFR\u2011TKI Ameile (almonertinib) globally.","og_url":"https:\/\/flcube.com\/?p=76808","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-27T06:54:14+00:00","article_modified_time":"2026-08-27T06:54:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2705.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76808#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76808"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked","datePublished":"2026-08-27T06:54:14+00:00","dateModified":"2026-08-27T06:54:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76808"},"wordCount":531,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76808#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2705.webp","keywords":["Finanical Reports","Hansoh Pharmaceutical","HKG: 3692"],"articleSection":["Company","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76808#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76808","url":"https:\/\/flcube.com\/?p=76808","name":"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76808#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76808#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2705.webp","datePublished":"2026-08-27T06:54:14+00:00","dateModified":"2026-08-27T06:54:15+00:00","description":"Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026, reporting revenue of approximately RMB 8.30 billion, up 11.7% year on year, and profit of approximately RMB 4.26 billion, a 35.8% year\u2011on\u2011year increase. Innovative drug revenue reached approximately RMB 7.09 billion, representing 85.4% of total revenue, while the company executed its first Newco\u2011model out\u2011licensing transaction \u2014 a landmark in its internationalization strategy \u2014 and continued to expand its flagship EGFR\u2011TKI Ameile (almonertinib) globally.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76808#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76808"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76808#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2705.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2705.webp","width":1080,"height":608,"caption":"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76808#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out\u2011Licensing Deal Marked"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2705.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76808"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76808\/revisions"}],"predecessor-version":[{"id":76812,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76808\/revisions\/76812"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76811"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}